| 1 | 08:40-09:00 | 专题报告 |
非小细胞肺癌免疫治疗进展和思考 |
|
||||
| 2 | 09:00-09:20 | 专题报告 |
EGFR突变阳性NSCLC临床研究思考及探索 |
|
||||
| 3 | 09:20-09:40 | 专题报告 |
小细胞肺癌的热点研究进展 |
|
||||
| 1 | 09:45-10:15 | 专题发言 |
围术期NSCLC治疗及进展 |
|
||||
| 2 | 10:15-10:45 | 专题发言 |
SCLC治疗及进展 |
|
||||
| 1 | 10:50-11:10 | 专题报告 |
早期肺癌免疫治疗问题与思考 |
|
||||
| 2 | 11:10-11:30 | 专题报告 |
III期不可切除NSCLC免疫治疗挑战与思考 |
|
||||
| 3 | 11:30-11:50 | 专题报告 |
晚期肺鳞癌的诊疗进展 |
|
||||
| 1 | 11:55-12:00 | 论文发言 |
晚期非小细胞肺癌患者免疫治疗后早期进展的影响因素分析及预测模型构建 |
|
||||
| 2 | 12:00-12:05 | 论文发言 |
Temporal Evolution and Attribution Analysis of Global Early-Onset Lung Cancer Disease Burden from 1990 to 2021 |
|
||||
| 3 | 12:05-12:10 | 论文发言 |
Fulminant Complement‑Mediated Endotheliopathy with HLH‑DIC Overlap Following PD‑1 Blockade After Complete Response in Lung Squamous Cell Carcinoma |
|
||||